New systemic therapy options for advanced sarcomas

Current Treatment Options in Oncology

Volumn 13, Issue 3, 2012, Pages 306-317

  Van Der Graaf, Winette T A ^a   Gelderblom, Hans ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ALK; cMET; Crizotinib; Denosumab; Eribulin; GIST; IGFR; Imatinib; Masitinib; Nilotinib; Pazopanib; Regorafenib; Ridaforolimus; Sarcoma; Sorafenib; Trabectedin

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTHRACYCLINE; CRIZOTINIB; DENOSUMAB; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ERIBULIN; FIGITUMUMAB; GEMCITABINE; IFOSFAMIDE; IMATINIB; MASITINIB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY R1507; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; NILOTINIB; PACLITAXEL; PAZOPANIB; PLACEBO; R 1507; REGORAFENIB; RIDAFOROLIMUS; RILOTUMUMAB; SCATTER FACTOR RECEPTOR; SOMATOMEDIN; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TRABECTEDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANGIOSARCOMA; ARTICLE; ASTHENIA; BONE MARROW TOXICITY; CANCER ADJUVANT THERAPY; CHORDOMA; CLEAR CELL SARCOMA; CONTINUOUS INFUSION; DERMATOFIBROSARCOMA PROTUBERANS; DESMOID TUMOR; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOCALCEMIA; JAW OSTEONECROSIS; LEIOMYOSARCOMA; LIPOSARCOMA; LIVER TOXICITY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; MYXOSARCOMA; NAUSEA; NEUTROPENIA; OSTEOSARCOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PIGMENTED VILLONODULAR SYNOVITIS; PLASMA CELL GRANULOMA; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHABDOMYOLYSIS; RHABDOMYOSARCOMA; SENSORY NEUROPATHY; SIDE EFFECT; SOFT TISSUE SARCOMA; STOMATITIS; SYNOVIAL SARCOMA; SYSTEMIC THERAPY; TREATMENT OUTCOME; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SARCOMA; SIGNAL TRANSDUCTION;

EID: 84865689142     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-012-0196-2     Document Type: Article

References (42)

1. AT Van Oosterom IR Judson J Verweij, et al. 2002 Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group Eur J Cancer 38 Suppl 5 S83 7 12528778 10.1016/S0959-8049(02)80608-6
2. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 16 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
3. H Choi C Charnsangavej SC Faria, et al. 2007 Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria J Clin Oncol 25 1753 9 17470865 10.1200/JCO.2006.07.3049
4. M Van Glabbeke J Verweij I Judson, et al. 2002 Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas Eur J Cancer 38 543 9 11872347 10.1016/S0959-8049(01)00398-7
5. F Grosso R Sanfilippo E Virdis, et al. 2009 Trabectedin in myxoid liposarcoma (MLS): a long-term analysis of a single-institution series Ann Oncol 20 1439 44 19465423 10.1093/annonc/mdp004 1:STN:280:DC%2BD1MrjtlKktw%3D%3D
6. A Gronchi BN Bui S Bonvalot, et al. 2012 Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma Ann Oncol 23 771 6 21642514 10.1093/annonc/mdr265 1:STN:280: DC%2BC383mtFWmsw%3D%3D
7. GD Demetri SP Chawla M von Mehren, et al. 2009 Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules J Clin Oncol 27 4188 96 19652065 10.1200/JCO.2008.21.0088 1:CAS:528:DC%2BD1MXhtF2jtLrL This paper is the only prospective randomised study of trabectedin in STS, although trabectedin is given in different schedules in both arms.
8. P Schöffski IL Ray-Coquard A Cioffi, et al. 2011 European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG). Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes Lancet Oncol 12 1045 52 21937277 10.1016/S1470-2045(11)70230-3
9. S Sleijfer I Ray-Coquard Z Papai, et al. 2009 Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-Soft tissue and Bone Sarcoma Group (EORTC study 62043) J Clin Oncol 27 3126 32 19451427 10.1200/JCO.2008.21.3223 1:CAS:528: DC%2BD1MXhtFWitb3P
10. Van der Graaf WT, Blay JY, Chawla S, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:1879-1886. This is the first phase III study in advanced or metastatic STS with meaningful positive results since the last decades.
11. George S, von Mehren M, Heinrich MC, et al. A multicenter phase II study of regorafenib in patients with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib and sunitinib. J Clin Oncol 2011; 29 (suppl; abstr 10007).
12. Park SH, Ryu MH, Ryoo BY, et al. Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. Invest New Drugs 2012 Jan 25 [Epub ahead of print].
13. I Ray-Coquard A Italiano E Bompas on behalf of the French Sarcoma Group (GSF/GETO), et al. 2012 Sorafenib for patients with advanced angiosarcoma: A phase II trial from the French Sarcoma Group (GSF/GETO) Oncologist 17 260 6 22285963 10.1634/theoncologist.2011-0237 1:CAS:528:DC%2BC38XlsV2ltr4%3D
14. G Grignani E Palmerini P Dileo, et al. 2012 A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study Ann Oncol 23 508 16 21527590 10.1093/annonc/mdr151 1:STN:280:DC%2BC387nt1ynsQ%3D%3D
15. GD Demetri PG Casali JY Blay, et al. 2009 A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors Clin Cancer Res 15 5910 6 19723647 10.1158/1078-0432.CCR-09-0542 1:CAS:528:DC%2BD1MXhtFars7rK
16. M Montemurro P Schöffski P Reichardt, et al. 2009 Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib Eur J Cancer 45 2293 7 19467857 10.1016/j.ejca.2009.04. 030 1:CAS:528:DC%2BD1MXhtVegsrfE
17. Reichardt P, Blay JY, Gelderblom H, et al. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann Oncol 2012 [Epub ahead of print].Phase III study that was courageous in this dismal third line GIST study population and needed to be done, but failed to show definite benefit of the drug.
18. A Le Cesne JY Blay BN Bui, et al. 2010 Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST) Eur J Cancer 46 1344 51 20211560 10.1016/j.ejca.2010.02.014
19. JC Soria C Massard N Magné, et al. 2009 Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers Eur J Cancer 45 2333 41 19541476 10.1016/j.ejca.2009.05.010 1:CAS:528:DC%2BD1MXhtVegs77P
20. SP Chawla AP Staddon LH Baker, et al. 2012 Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas J Clin Oncol 30 78 84 22067397 10.1200/JCO.2011.35.6329 1:CAS:528:DC%2BC38XislOlurY%3D
21. Chawla SP, Blay JY, Ray-Coquard IL, et al. Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy. J Clin Oncol 2011;29 (suppl; abstr 10005).
22. Merck. NDA 22-576 (ridaforolimus tablets)oncologic drugs advisory committeebriefing document. 2012. http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ OncologicDrugsAdvisoryCommittee/UCM296305.pdf Accessed March 2012.
23. D Thomas R Henshaw K Skubitz, et al. 2010 Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study Lancet Oncol 11 275 80 20149736 10.1016/S1470-2045(10)70010-3 1:CAS:528:DC%2BC3cXisFGrtrw%3D This is a phase II of the most active drug in sarcoma, although a relatively non-malignant form (giant cell tumor of bone), but still a disease that can lead to severe morbidity.
24. Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:1097-1104.
25. H Joensuu M Eriksson K Sundby Hall, et al. 2012 One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial JAMA 307 1265 72 22453568 10.1001/jama.2012.347 1:CAS:528: DC%2BC38XltVCks78%3D Practice changing study on the benefit (both progression-free and overall survival) of imatinib in high risk GIST.
26. JY Blay H El Sayadi P Thiesse J Garret I Ray-Coquard 2008 Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT) Ann Oncol 19 821 2 18296418 10.1093/annonc/mdn033
27. PA Cassier H Gelderblom S Stacchiotti, et al. 2012 Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis Cancer 118 1649 55 21823110 10.1002/cncr.26409 1:CAS:528:DC%2BC38XjtFyhsLY%3D
28. S Stacchiotti A Longhi V Ferraresi, et al. 2012 Phase II study of imatinib in advanced chordoma J Clin Oncol 30 914 20 22331945 10.1200/JCO.2011.35.3656 1:CAS:528:DC%2BC38Xmt1Sgs74%3D
29. R Chugh JK Wathen SR Patel, et al. 2010 Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial Clin Cancer Res 16 4884 4491 20724445 10.1158/1078-0432.CCR-10-1177 1:CAS:528:DC%2BC3cXht1aktbnL
30. P Rutkowski M van Glabbeke CJ Rankin, et al. 2010 Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials J Clin Oncol 28 1772 9 20194851 10.1200/JCO.2009.25.7899 1:CAS:528:DC%2BC3cXmtVyhu74%3D
31. B Rikhof S de Jong AJ Suurmeijer C Meijer WT van der Graaf 2009 The insulin-like growth factor system and sarcomas J Pathol 217 469 82 19148905 10.1002/path.2499 1:CAS:528:DC%2BD1MXjvFOmu7o%3D
32. D Olmos DS Tan RL Jones IR Judson, et al. 2010 Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside Cancer J 16 183 94 20526094 10.1097/PPO.0b013e3181dbebf9 1:CAS:528:DC%2BC3cXovV2rt74%3D
33. D Olmos S Postel-Vinay LR Molife, et al. 2010 Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study Lancet Oncol 11 129 35 20036194 10.1016/S1470-2045(09)70354-7 1:CAS:528:DC%2BC3cXhtlGgtbs%3D
34. AS Pappo SR Patel J Crowley, et al. 2011 R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study J Clin Oncol 29 4541 7 22025149 10.1200/JCO.2010.34.0000 1:CAS:528:DC%2BC38XhtlKmtbg%3D
35. H Juergens NC Daw B Geoerger, et al. 2011 Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma J Clin Oncol 29 4534 40 22025154 10.1200/JCO.2010.33.0670 1:CAS:528:DC%2BC38XhtlKmtb0%3D
36. ED Fleuren YM Versleijen-Jonkers AC van de Luijtgaarden, et al. 2011 Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507 Clin Cancer Res 17 7693 703 22038993 10.1158/1078-0432.CCR- 11-1488 1:CAS:528:DC%2BC3MXhs1CqtrnJ
37. Naing A, LoRusso P, Fu S, et al. Insulin growth factor-receptor (IGF-1R) Antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with reflectory Ewing's sarcoma family tumors. Clin Cancer Res 2012;18:2625-31.
38. JE Butrynski DR D'Adamo JL Hornick, et al. 2010 Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor N Engl J Med 363 1727 33 20979472 10.1056/NEJMoa1007056 1:CAS:528:DC%2BC3cXhtlKitL%2FI This and other observations provided the rationale for the EORTC-CREATE study.
39. JC Van Gaal UE Flucke MHA Roeffen, et al. 2012 Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications J Clin Oncol 30 308 15 22184391 10.1200/JCO.2011.37.8588
40. IJ Davis AW McFadden Y Zhang A Coxon TL Burgess AJ Wagner DE Fisher 2010 Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma Cancer Res 70 639 45 20068147 10.1158/0008-5472.CAN-09-1121 1:CAS:528:DC%2BC3cXltlWqsQ%3D%3D
41. CF Gao Q Xie YW Zhang, et al. 2009 Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma Mol Cancer Ther 8 2803 10 19825800 10.1158/1535-7163.MCT-09-0125 1:CAS:528:DC%2BD1MXht1Cqur7M
42. HJ Jun J Lee H Lim do, et al. 2010 Expression of MET in alveolar soft part sarcoma Med Oncol 27 459 65 19472090 10.1007/s12032-009-9234-8 1:CAS:528:DC%2BC3cXlsVSqt74%3D